Cisplatin liver toxicity
WebOct 26, 2005 · It is possible that cisplatin-induced oxidative stress and CYP2E1-mediated oxidative stress synergize to produce hepatotoxicity. In the present study, the effect of increased CYP2E1 expression on cisplatin-induced hepatotoxicity was investigated. WebCisplatin may be inadvisable if you have a history of severe allergic reaction to cisplatin, carboplatin, other platinum-containing formulations or mannitol. Do not receive any kind …
Cisplatin liver toxicity
Did you know?
WebIts stereoisomer transplatin does not have any toxicity at equimolar concentrations, and it also possesses little antitumor activity. In this study, subcellular localization of both the platinum isomers was examined in the liver and kidney of the mouse 24 hours following the drug administration. WebOct 5, 2014 · Oxidative stress is the one of most important mechanisms involved in cisplatin toxicity. The mitochondrion is the primary target for cisplatin induced oxidative stress, ... Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats. Chem.Biol.Interact. 2007; 170:177–186. [Google Scholar]
WebCisplatin (CP) is a potent and extensively used chemotherapeutic agent. There is paucity of literature involving role of mitochondria in mediating CP-induced hepatic toxicity, and its underlying mechanism remains unclear. Oxidative stress is a well-established biomarker of the mitochondrial toxicity. WebApr 5, 2024 · Cisplatin mediates its tumorcidal effects via a number of different cytotoxic mechanisms. Although it is best known for DNA damage, cisplatin also causes cytoplasmic organelle dysfunction particularly with …
WebNov 12, 2024 · Nephrotoxicity: cisplatin injection can cause severe renal toxicity, including acute renal failure. Severe renal toxicities are dose-related and cumulative. Consider dose reductions or alternative treatments in patients with renal impairment. Peripheral Neuropathy: cisplatin injection can cause dose-related peripheral neuropathy. WebJun 21, 2024 · Hepatoblastoma is a rare primary liver cancer with an age-adjusted incidence of 0.13 patients per 100,000 population. 1 Hepatoblastoma can be categorized as standard-risk or high-risk disease...
WebSep 15, 2024 · Liver injury from cisplatin is rare and when it does occur, the severity in published cases was generally mild and the outcome benign. There is likely to be cross sensitivity to liver toxicities of the various platinum coordination complexes and …
WebFeb 11, 2024 · Cisplatin is a cytotoxic drug that triggers several toxicities. However, nephrotoxicity and ototoxicity remain major clinical limitations. The aim of our study was to evaluate the incidence of chemotherapy toxicity induced by cisplatin and to analyze the influence of risk factors in the Tunisian population. flyt thor valhallaWebFeb 2, 2024 · The liver is an important central organ for metabolism and detoxification in the human body and is susceptible to many factors, such as excessive alcohol consumption, hepatoviruses, various toxins, and drugs, leading to the development of liver diseases. ... Toxicity of Cisplatin to the central Nervous System of Male Rabbits. Bter 74 (3), 223 ... flyt til barcelonaWebAn association between cisplatin administration and hepatotoxicity is proposed in this patient. Conclusions: This patient may have experienced cisplatin-induced liver … flyttkartong clas ohlsonWeb2 days ago · LiverTox®provides up-to-date, unbiased and easily accessed information on the diagnosis, cause, frequency, clinical patterns and management of liver injury … green pumpkin chatterbaitWebWorld Health Organization green pumpkin fishing wormWebCisplatin has demonstrated efficacy against various types of cancers such as germ cell tumors, sarcomas, carcinomas as well as lymphomas. The current study presents a pharmacological review on the drug including its mechanism of action, resistance mechanism, and toxicity as well as its clinical applications. flyttlass wikipediaWebApr 12, 2024 · Currently, gemcitabine/cisplatin is first-line therapy for advanced iCCA based on the ABC-02 clinical trial (ClinicalTrials.gov identifier NCT02170090). That phase 3 study included 410 patients with locally advanced or metastatic CCA, gallbladder cancer, or ampullary cancer. flyttsmart simplex